Nkarta
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1150 Veterans Blvd, South San Francisco,...Phone Number
(925) 407-1049Website
www.nkartatx.comRevenue
-Stock Symbol
NKTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body.Explore more
Nkarta Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nkarta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Nkarta launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Nkarta has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Nkarta has new funding data
Check out if Nkarta is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Nkarta
Nkarta, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Nkarta recently announced quarterly report
Click to see if Nkarta had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Nkarta as Masked Content
Find more new buyers
Compare Similar Companies to Nkarta
Compare insights from companies similar to Nkarta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nkarta is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nkarta is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nkarta.
Nkarta financials insights
Gather financial insights about Nkarta, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$11M
2019
Series B
$114M
Nkarta Tech Stack
A closer look at the technologies used by Nkarta
Most Recent Scoops
Person-Based
Earnings, Clinical Operations, Finance, Investor Relations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Nkarta News & Media
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol amendments are designed to alleviate the need for overnight stays and reduce the overall burden on patieNkarta to Participate in Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference.Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience, right-sized our workforce to be a responsible steward of investor capital,Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nkarta
Sign Up For FreeTo access detailed company insights
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient... Read More
